HomeBUSINESS
BUSINESS

Mitsubishi Tanabe to Acquire Stelic, Adding Nucleic Acid Drugs to Lineup to Accelerate Business Development in US
(Nov.6.2017)

Mitsubishi Tanabe President Masayuki Mitsuka
Mitsubishi Tanabe Pharma said on November 1 that it will acquire Tokyo-based biotech company Stelic Institute. Stelic’s pipeline includes STNM01, a siRNA that inhibits carbohydrate sulfotransferase 15 (CHST15), for the treatment of GI diseases including ulcerative colitis. Mitsubishi Tanabe aims to add it to its autoimmune disease product lineup for business development in the US ...
(LOG IN FOR FULL STORY)

News Calendar